Rahul D. Ballal sold $1.1M of AGIO
director at AGIOS PHARMACEUTICALS, INC.. 20,000 shares at an average of $55.86, traded Nov 7, 2024, filed Nov 12, 2024.
Score components
- +15RoleDirector
- +25Trade size$1.1M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -35.3%, 3m -44.7%, 6m -51.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001439222-24-000142, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2024 | MOption exercise Common stock10b5-1 | +10,000 | $25.99 | $260k | 17,992 | Nov 12, 2024 |
| Nov 7, 2024 | SOpen-market sale Common stock10b5-1 | -8,132 | $53.32 | $434k | 9,860 | Nov 12, 2024 |
| Nov 7, 2024 | SOpen-market sale Common stock10b5-1 | -1,868 | $54.41 | $102k | 7,992 | Nov 12, 2024 |
| Nov 8, 2024 | MOption exercise Common stock10b5-1 | +10,000 | $25.99 | $260k | 17,992 | Nov 12, 2024 |
| Nov 8, 2024 | SOpen-market sale Common stock10b5-1 | -3,571 | $57.24 | $204k | 14,421 | Nov 12, 2024 |
| Nov 8, 2024 | SOpen-market sale Common stock10b5-1 | -4,929 | $58.57 | $289k | 9,492 | Nov 12, 2024 |
| Nov 8, 2024 | SOpen-market sale Common stock10b5-1 | -1,500 | $59.21 | $89k | 7,992 | Nov 12, 2024 |
| Nov 7, 2024 | MOption exercise Stock option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 27,947 | Nov 12, 2024 |
| Nov 8, 2024 | MOption exercise Stock option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 17,947 | Nov 12, 2024 |
Related signals
Other insiders at AGIOS PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | AGIOS PHARMACEUTICALS, INC. | Brian Goff Chief Executive Officer | $627k 18,700 shares | -16% | |
| 5Weak | AGIOS PHARMACEUTICALS, INC. | Tsveta Milanova Chief Commercial Officer | $93k 2,770 shares | -10% | |
| 9Weak | AGIOS PHARMACEUTICALS, INC. | Cecilia Jones Chief Financial Officer | $60k 1,780 shares | -6% | |
| 5Weak | AGIOS PHARMACEUTICALS, INC. | Sarah Gheuens Chief Medical Officer | $98k 2,909 shares | -5% | |
| 5Weak | AGIOS PHARMACEUTICALS, INC. | James William Burns Chief Legal Officer | $94k 2,799 shares | -9% | |
| 0Weak | AGIOS PHARMACEUTICALS, INC. | Jacqualyn A Fouse director | $194k 7,497 shares | -5% | |
| 12Weak | AGIOS PHARMACEUTICALS, INC. | Theodore James Washburn Jr. Principal Accounting Officer | $59k 1,655 shares | -26% | |
| 6Weak | AGIOS PHARMACEUTICALS, INC. | Sarah Gheuens Chief Medical Officer | $142k 4,005 shares | -8% | |
| 27Weak | AGIOS PHARMACEUTICALS, INC. | Brian Goff Chief Executive Officer | $460k 12,947 shares | -15% | |
| 2Weak | AGIOS PHARMACEUTICALS, INC. | Tsveta Milanova Chief Commercial Officer | $60k 1,681 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.